Kato (Hong Kong) Holdings (2189) has a market capitalization of approximately HK$490M, trading at HK$0.49 on the HKSE. Market cap moves with the live share price.
Kato (Hong Kong) Holdings's trailing twelve-month P/E ratio is 14.3x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Kato (Hong Kong) Holdings runs a net profit margin of 9.7%, a gross margin of 38.8%, and an operating margin of 26.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Kato (Hong Kong) Holdings reported revenue of HK
Kato (Hong Kong) Holdings offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Kato (Hong Kong) Holdings carries a debt-to-equity ratio of 0.60x and a current ratio of 1.16x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kato (Hong Kong) Holdings (2189) the key facts are: market cap HK$490M, P/E 14.3x, revenue HK
Get Kato (Hong Kong) Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.